Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan

Karen-Lise Garm Spindler; Niels Pallisgaard; Ivan Vogelius; Leif Anders Jakobsen

doi:10.1158/1078-0432.CCR-11-0564

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan

Karen-Lise Garm Spindler, Niels Pallisgaard, Ivan Vogelius, Leif Anders Jakobsen

234 Citationer (Scopus)

Abstract

The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.

Originalsprog	Engelsk
Tidsskrift	Clinical Cancer Research
Vol/bind	18
Udgave nummer	4
Sider (fra-til)	1177-85
Antal sider	9
ISSN	1078-0432
DOI	https://doi.org/10.1158/1078-0432.CCR-11-0564
Status	Udgivet - 2012

Adgang til dokumentet

10.1158/1078-0432.CCR-11-0564

Andre filer og links

Link to publication in Scopus

Citationsformater

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. / Spindler, Karen-Lise Garm; Pallisgaard, Niels; Vogelius, Ivan et al.
I: Clinical Cancer Research, Bind 18, Nr. 4, 2012, s. 1177-85.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{9d84b672243e48589809bdaf9b2f025c,

title = "Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan",

abstract = "The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.",

keywords = "Adult, Aged, Aged, 80 and over, Alleles, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colorectal Neoplasms, DNA, Neoplasm, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prognosis, Proto-Oncogene Proteins, Proto-Oncogene Proteins B-raf, Treatment Outcome, ras Proteins",

author = "Spindler, \{Karen-Lise Garm\} and Niels Pallisgaard and Ivan Vogelius and Jakobsen, \{Leif Anders\}",

note = "{\textcopyright}2012 AACR.",

year = "2012",

doi = "10.1158/1078-0432.CCR-11-0564",

language = "English",

volume = "18",

pages = "1177--85",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

TY - JOUR

T1 - Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan

AU - Spindler, Karen-Lise Garm

AU - Pallisgaard, Niels

AU - Vogelius, Ivan

AU - Jakobsen, Leif Anders

PY - 2012

Y1 - 2012

N2 - The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.

AB - The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Alleles

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Camptothecin

KW - Colorectal Neoplasms

KW - DNA, Neoplasm

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Mutation

KW - Neoplasm Metastasis

KW - Prognosis

KW - Proto-Oncogene Proteins

KW - Proto-Oncogene Proteins B-raf

KW - Treatment Outcome

KW - ras Proteins

UR - https://www.scopus.com/pages/publications/84857076207

U2 - 10.1158/1078-0432.CCR-11-0564

DO - 10.1158/1078-0432.CCR-11-0564

M3 - Journal article

C2 - 22228631

SN - 1078-0432

VL - 18

SP - 1177

EP - 1185

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater